Literature DB >> 29296387

Evaluation of ray tracing and Monte Carlo algorithms in dose calculation and clinical outcomes for robotic stereotactic body radiotherapy of lung cancers.

Steve E Braunstein1, Sebastian A Dionisio1, Michael W Lometti1, Dilini S Pinnaduwage1, Cynthia F Chuang1, Sue S Yom1, Alexander R Gottschalk1, Martina Descovich1.   

Abstract

PURPOSE/
OBJECTIVE: Dose calculation in treatment planning must account for tissue heterogeneity, especially for tumors within low-density lung tissues. While Monte Carlo (MC) calculation methods are the most accurate, Ray Tracing (RT) methods are also commonly employed. We evaluated dose calculation differences between the RT and MC algorithms in central and peripheral lung tumors treated with CyberKnife SBRT to determine which planning parameters may predict dose differences. We also examined clinical outcomes of local-regional control (LRC) and long-term treatment-related toxicity as a function of calculation method. MATERIALS/
METHODS: A retrospective series of 70 patient plans (19 central and 51 peripheral lung lesions) treated between 2009 and 2011 were analyzed. Among those, 33 were primary lung cancer and 37 were metastatic lesions. Thirty-three treatment plans were developed with the RT method, and 37 plans used MC. Groups were recalculated with the reciprocal method for dose comparison. Parameters examined to quantify dose differences between the two algorithms included: dose delivered to 95% (D95) of the planning target volume (PTV), dose heterogeneity, and dose to organs at risk (OAR). Dose differences were analyzed as a function of target volume, distance to soft tissue, and fraction of target overlap with soft tissue. For the subset of primary lung tumors, LRC was assessed radiographically at a median follow-up of 19 months (mo) (range, 2 to 41 mo).
RESULTS: Compared to MC, the RT algorithm largely overestimated the dose delivered to the PTV. The dose difference between RT and MC plans correlated to the volume of PTV overlapping with soft tissue; the smaller the overlap volume, the larger the dose differences between RT and MC. Compared to MC, the RT algorithm overestimated the dose delivered to 10% of the ipsilateral lung (D10%). Evidence of local progression was noted in only one of the 31 patients treated for primary lung malignancy. DFS and OS were not significantly different between RT and MC plans.
CONCLUSION: There is a significant range of discordance between MC and RT dose calculations for SBRT treated peripheral lung tumors. While variation is correlated to target size and proximity to soft tissue, no single parameter can reliably predict dose differences. Ultimately, local control and long-term toxicity appear independent of the dose calculation method.

Entities:  

Keywords:  Dose Calculation; Heterogeneity; Lung Cancer; Monte Carlo; Ray Tracing; SBRT

Year:  2014        PMID: 29296387      PMCID: PMC5725332     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  43 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.

Authors:  Sashendra Senthi; Frank J Lagerwaard; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  Lancet Oncol       Date:  2012-06-22       Impact factor: 41.316

3.  A study of the accuracy of cyberknife spinal radiosurgery using skeletal structure tracking.

Authors:  Anthony K Ho; Dongshan Fu; Cristian Cotrutz; Steven L Hancock; Steven D Chang; Iris C Gibbs; Calvin R Maurer; John R Adler
Journal:  Neurosurgery       Date:  2007-02       Impact factor: 4.654

Review 4.  Radiotherapy for lung cancer in the elderly.

Authors:  Neil Bayman; Nooreen Alam; Corinne Faivre-Finn
Journal:  Lung Cancer       Date:  2010-01-15       Impact factor: 5.705

5.  Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer.

Authors:  Eva M Bongers; Cornelis J A Haasbeek; Frank J Lagerwaard; Ben J Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2011-12       Impact factor: 15.609

6.  Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group.

Authors:  Nitin Ohri; Maria Werner-Wasik; Inga S Grills; José Belderbos; Andrew Hope; Di Yan; Larry L Kestin; Matthias Guckenberger; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-01       Impact factor: 7.038

7.  Pulmonary function testing after stereotactic body radiotherapy to the lung.

Authors:  Muath Bishawi; Bong Kim; William H Moore; Thomas V Bilfinger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-04       Impact factor: 7.038

8.  A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.

Authors:  Mark A Henderson; David J Hoopes; James W Fletcher; Pei-Fen Lin; Mark Tann; Constantin T Yiannoutsos; Mark D Williams; Achilles J Fakiris; Ronald C McGarry; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-25       Impact factor: 7.038

9.  Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer.

Authors:  Neil Kopek; Merete Paludan; Jørgen Petersen; Anders Traberg Hansen; Cai Grau; Morten Høyer
Journal:  Radiother Oncol       Date:  2009-06-24       Impact factor: 6.280

10.  Image-guided robotic stereotactic radiation therapy with fiducial-free tumor tracking for lung cancer.

Authors:  Jean-Emmanuel Bibault; Bernard Prevost; Eric Dansin; Xavier Mirabel; Thomas Lacornerie; Eric Lartigau
Journal:  Radiat Oncol       Date:  2012-06-24       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.